pioglitazone has been researched along with Pneumonia in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Pneumonia: Infection of the lung often accompanied by inflammation.
Excerpt | Relevance | Reference |
---|---|---|
"Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo." | 9.22 | Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. ( Anderson, JR; Bailey, H; Harrison, TW; Hodgson, DB; Knox, AJ; Mortimer, K; Pang, L; Shaw, DE; Smith, KM, 2016) |
"Pioglitazone treatment was associated with increased expression of chemokine (Cxcl1, Cxcl2, and Ccl20) and cytokine genes (Tnfa, Il6, and Cfs3) in bronchial brushes obtained 6 h after infection." | 5.72 | The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia. ( de Vos, AF; Ferreira, BL; Otto, NA; Ramirez-Moral, I; Salomão, R; van der Poll, T, 2022) |
"Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo." | 5.22 | Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. ( Anderson, JR; Bailey, H; Harrison, TW; Hodgson, DB; Knox, AJ; Mortimer, K; Pang, L; Shaw, DE; Smith, KM, 2016) |
"Pioglitazone treatment was associated with increased expression of chemokine (Cxcl1, Cxcl2, and Ccl20) and cytokine genes (Tnfa, Il6, and Cfs3) in bronchial brushes obtained 6 h after infection." | 1.72 | The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia. ( de Vos, AF; Ferreira, BL; Otto, NA; Ramirez-Moral, I; Salomão, R; van der Poll, T, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Ferreira, BL | 1 |
Ramirez-Moral, I | 1 |
Otto, NA | 1 |
Salomão, R | 1 |
de Vos, AF | 1 |
van der Poll, T | 1 |
Malekinejad, H | 1 |
Khoramjouy, M | 1 |
Hobbenaghi, R | 1 |
Amniattalab, A | 1 |
Anderson, JR | 1 |
Mortimer, K | 1 |
Pang, L | 1 |
Smith, KM | 1 |
Bailey, H | 1 |
Hodgson, DB | 1 |
Shaw, DE | 1 |
Knox, AJ | 1 |
Harrison, TW | 1 |
Sharma, R | 1 |
Kaundal, RK | 1 |
Sharma, SS | 1 |
Rydén, L | 1 |
Thráinsdóttir, I | 1 |
Swedberg, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
PPAR-gamma: a Novel Therapeutic Target in Asthma?[NCT01134835] | Phase 4 | 68 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to safety concerns with pioglitazone) | ||
PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for pioglitazone and Pneumonia
Article | Year |
---|---|
Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.
Topics: Adult; Aged; Asthma; Chemokine CCL2; Chemokine CXCL10; Double-Blind Method; Eosinophil Cationic Prot | 2016 |
4 other studies available for pioglitazone and Pneumonia
Article | Year |
---|---|
The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia.
Topics: Animals; Epithelial Cells; Hypoglycemic Agents; Inflammation; Mice; Pioglitazone; Pneumonia; PPAR ga | 2022 |
Atorvastatin attenuates the paraquat-induced pulmonary inflammation via PPARγ receptors: a new indication for atorvastatin.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Heptanoic Acids; Herbicides; Interleukin-6; Lung; M | 2014 |
Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs.
Topics: Administration, Inhalation; Animals; Bronchoalveolar Lavage Fluid; Escherichia coli Proteins; Guinea | 2009 |
Adjudication of serious heart failure in patients from PROactive.
Topics: Heart Failure; Hospital Mortality; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Pneum | 2007 |